

Jerzy Jaroszewicz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7247534/publications.pdf>

Version: 2024-02-01

102
papers

3,814
citations

201385

27
h-index

138251

58
g-index

105
all docs

105
docs citations

105
times ranked

5476
citing authors

#	ARTICLE	IF	CITATIONS
1	Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection. <i>Journal of Clinical Medicine</i> , 2022, 11, 389.	1.0	2
2	High in-hospital and post-discharge mortality in patients with a pre-existing diagnosis of heart failure hospitalized due to COVID-19. <i>Kardiologia Polska</i> , 2022, 80, 90-92.	0.3	1
3	Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland. <i>Vaccines</i> , 2022, 10, 557.	2.1	15
4	Significant Decrease in the Prevalence of Anxiety and Depression after Hepatitis C Eradication. <i>Journal of Clinical Medicine</i> , 2022, 11, 3044.	1.0	2
5	High prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders in eastern Poland. <i>Archives of Medical Science</i> , 2021, 17, 675-681.	0.4	3
6	Neurologic manifestations of COVID-19. Authors' reply. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 208-209.	0.3	0
7	SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy. <i>Clinical Neurology and Neurosurgery</i> , 2021, 201, 106451.	0.6	13
8	Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Cer2 Study. <i>Liver International</i> , 2021, 41, 1789-1801.	1.9	10
9	Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. <i>Journal of Clinical Medicine</i> , 2021, 10, 1583.	1.0	21
10	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 487-496.	0.3	48
11	Acute Coronary Tree Thrombosis After Vaccination for COVID-19. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, e103-e104.	1.1	46
12	Impact of Kidney Failure on the Severity of COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 2042.	1.0	13
13	Symptom-based early-stage differentiation between SARS-CoV-2 versus other respiratory tract infections – Upper Silesia pilot study. <i>Scientific Reports</i> , 2021, 11, 13580.	1.6	5
14	Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3359-3366.	1.6	17
15	Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. <i>Journal of Clinical Medicine</i> , 2021, 10, 3280.	1.0	13
16	Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy. <i>Cancers</i> , 2021, 13, 3694.	1.7	16
17	Experimental and CFD Simulations of the Aerosol Flow in the Air Ventilating the Underground Excavation in Terms of SARS-CoV-2 Transmission. <i>Energies</i> , 2021, 14, 4743.	1.6	4
18	HCV resistance-associated substitutions following direct-acting antiviral therapy failure – Real-life data from Poland. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104949.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Brain-derived neurotrophic factor as a potential diagnostic marker in minimal hepatic encephalopathy. <i>Clinical and Experimental Hepatology</i> , 2021, 7, 117-124.	0.6	4
20	Diagnosis and therapy of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of November 12, 2021. Annex no. 1 to the Recommendations of April 26, 2021. <i>Polish Archives of Internal Medicine</i> , 2021, 131, .	0.3	6
21	Screening Support System Based on Patient Survey Data – Case Study on Classification of Initial, Locally Collected COVID-19 Data. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 10790.	1.3	4
22	Real-world experience with Grazoprevir/Elbasvir in the treatment of previously – difficult to treat – patients infected with hepatitis C virus genotype 1 and 4. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1238-1246.	1.4	9
23	Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. <i>Advances in Medical Sciences</i> , 2020, 65, 12-17.	0.9	5
24	Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 36, 1944-1952.	1.4	9
25	Searching for the optimal population for hepatitis C virus screening in Poland. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 74-76.	0.6	3
26	Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfecting patients treated with DAA. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1045-1054.	2.0	12
27	Lymphocyte-To-Monocyte Ratio as the Best Simple Predictor of Bacterial Infection in Patients with Liver Cirrhosis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1727.	1.2	33
28	High CD163 Expression on Classical Monocytes Is Associated with Immune Control of HBV Infection in Noncirrhotic Patients. <i>Mediators of Inflammation</i> , 2020, 2020, 1-13.	1.4	17
29	Serum Concentrations of Th17-Associated Interleukins and Autoimmune Phenomena are Associated with the Degree of Liver Damage in Alcoholic Liver Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 26, 269-274.	0.5	11
30	Changes of patient profile, treatment effectiveness and safety during 4 years access to interferon-free therapy for hepatitis C virus infection. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 163-172.	0.3	14
31	Recommendations of management in SARS-CoV-2 infection of the Polish Association of Epidemiologists and Infectiologists. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 352-357.	0.3	51
32	Annex #1 as of 8 June 2020 to: Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 557-558.	0.3	20
33	Neurological symptoms as a clinical manifestation of COVID-19: implications for internists. <i>Polish Archives of Internal Medicine</i> , 2020, 131, 54-62.	0.3	11
34	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 2 as of October 13, 2020. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 915-918.	0.3	30
35	Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study. <i>Polish Archives of Internal Medicine</i> , 2020, 131, 103-110.	0.3	12
36	Clinical Usefulness of the Inhibitory Control Test (ICT) in the Diagnosis of Minimal Hepatic Encephalopathy. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3645.	1.2	5

#	ARTICLE	IF	CITATIONS
37	Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 195-202.	0.6	22
38	Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 215-223.	0.6	1
39	Soluble immune markers in the different phases of chronic hepatitis B virus infection. <i>Scientific Reports</i> , 2019, 9, 14118.	1.6	14
40	Chronic hepatitis B virus infection is associated with decreased serum 25(OH)D concentration in non-cirrhotic patients. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 75-80.	0.6	6
41	Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-9.	0.8	12
42	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979.	2.9	21
43	Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 93-100.	0.5	9
44	siRNA drug development against hepatitis B virus infection. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 609-617.	1.4	27
45	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	3.7	1,241
46	Predictive power of Model for End-Stage Liver Disease and Child-Turcotte-Pugh score for mortality in cirrhotic patients. <i>Clinical and Experimental Hepatology</i> , 2018, 4, 240-246.	0.6	9
47	The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 580.	1.3	2
48	Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). <i>Clinical and Experimental Hepatology</i> , 2018, 4, 153-157.	0.6	15
49	Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience. <i>Hepatitis Monthly</i> , 2018, 18, .	0.1	2
50	Surgical treatment of liver tumors – own experience and literature review. <i>Clinical and Experimental Hepatology</i> , 2017, 1, 1-8.	0.6	8
51	The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease. <i>Clinical and Experimental Hepatology</i> , 2017, 3, 127-134.	0.6	20
52	Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease. <i>Mediators of Inflammation</i> , 2017, 2017, 1-8.	1.4	9
53	Recommendations for the treatment of hepatitis B in 2017. <i>Clinical and Experimental Hepatology</i> , 2017, 2, 35-46.	0.6	15
54	Normalizing serum hepcidin but not Î±1-antitrypsin level during effective treatment of chronic hepatitis C. <i>Clinical and Experimental Hepatology</i> , 2017, 4, 203-208.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Hepatology topics of special interest from Central Europe (Czech Republic, Hungary, Poland,) Tj ETQq1 1 0.784314,rgBT /Overlock 10 T	0.6	0
56	Hepatitis E virus infection—a new threat for Europe. <i>Przegląd Epidemiologiczny</i> , 2016, 70, 11-4, 103-6.	0.4	3
57	Review article Immune regulation and viral diversity as correlates of natural and treatment induced immune control in persistent hepatitis B virus (HBV) infection. <i>Clinical and Experimental Hepatology</i> , 2015, 2, 35-38.	0.6	8
58	Original article Distribution of HBV genotypes in Poland. <i>Clinical and Experimental Hepatology</i> , 2015, 1, 1-4.	0.6	9
59	Effect of psoriasis activity on serum adiponectin and leptin levels. <i>Postepy Dermatologii I Alergologii</i> , 2015, 2, 101-106.	0.4	43
60	Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1229-1239.	1.9	23
61	Prevalence and Risk Factors of HCV/HIV Co-Infection and HCV Genotype Distribution in North-Eastern Poland. <i>Hepatitis Monthly</i> , 2015, 15, e27740.	0.1	13
62	Serum cytochrome c and m30â€œneoepitope of cytokeratinâ€œ18 in chronic hepatitis C. <i>Liver International</i> , 2014, 34, 544-550.	1.9	27
63	A pill for <scp>HCV</scp> â€œ myth or foreseeable future?. <i>Liver International</i> , 2014, 34, 6-11.	1.9	20
64	Emerging treatments for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 461-475.	1.0	30
65	Assessment of serum IGF-1 and adipokines related to metabolic dysfunction in HIV-infected adults. <i>Cytokine</i> , 2013, 64, 97-102.	1.4	13
66	Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. <i>Cytokine</i> , 2013, 61, 690.	1.4	3
67	Metabolic syndrome and hepatitis C infection â€œ brothers in arms. <i>Liver International</i> , 2013, 33, 1135-1137.	1.9	4
68	Interferon Î±â€œStimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1. <i>Journal of Infectious Diseases</i> , 2012, 205, 1351-1362.	1.9	38
69	Improved Immune Status Corresponds with Long-Term Decline of Quantitative Serum Hepatitis B Surface Antigen in HBV/HIV Co-infected Patients. <i>Viral Immunology</i> , 2012, 25, 442-447.	0.6	15
70	Update on alisporivir in treatment of viral hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 375-382.	1.9	44
71	Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. <i>Hepatology</i> , 2012, 55, 695-708.	3.6	158
72	Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection. <i>PLoS ONE</i> , 2012, 7, e43143.	1.1	42

#	ARTICLE	IF	CITATIONS
73	Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. <i>Journal of Clinical Virology</i> , 2011, 50, 292-296.	1.6	76
74	Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide Analogues. <i>Antiviral Therapy</i> , 2011, 16, 915-924.	0.6	76
75	Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. <i>Liver International</i> , 2011, 31, 1395-1405.	1.9	42
76	Dual Function of the NK Cell Receptor 2B4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells. <i>PLoS Pathogens</i> , 2011, 7, e1002045.	2.1	102
77	Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. <i>Journal of Hepatology</i> , 2010, 52, 514-522.	1.8	355
78	Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. <i>Cytokine</i> , 2010, 52, 225-229.	1.4	35
79	Interferon-Î±-Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 1885-1897.e10.	0.6	177
80	Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2010, 16, 1747.	1.4	15
81	Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis. <i>Regulatory Peptides</i> , 2008, 147, 25-28.	1.9	68
82	Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: Possible association with hepatic function impairment. <i>Cytokine</i> , 2008, 44, 14-17.	1.4	29
83	Serum prohepcidin reflects the degree of liver function impairment in liver cirrhosis. <i>Biomarkers</i> , 2008, 13, 478-485.	0.9	22
84	Pigment epithelium-derived factor in ulcerative colitis: Possible relationship with disease activity. <i>Regulatory Peptides</i> , 2007, 140, 1-4.	1.9	7
85	The influence of protease inhibitors on a frequency of lipid metabolism disturbances occurrence in HIV-1 infected patients. <i>HIV and AIDS Review</i> , 2007, 6, 19-23.	0.1	1
86	Slowly progressing cutaneous T-cell lymphoma in HIV infected individual. <i>HIV and AIDS Review</i> , 2007, 6, 33-35.	0.1	1
87	Serum concentrations of Î±-defensins in patients with different stages of HIV-infection. <i>HIV and AIDS Review</i> , 2007, 6, 20-22.	0.1	1
88	Specifically targeted antiviral therapy for hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2007, 13, 5673.	1.4	46
89	Concentrations of Soluble Fas and Soluble Fas Ligand as Indicators of Programmed Cell Death among Patients Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus. <i>Viral Immunology</i> , 2006, 19, 570-575.	0.6	5
90	Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration. <i>Antiviral Therapy</i> , 2006, 11, 641-5.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Does Haart Improve Renal Function? An Association between Serum Cystatin C Concentration, HIV Viral Load and Haart Duration. <i>Antiviral Therapy</i> , 2006, 11, 641-646.	0.6	23
92	Acute Hepatitis E Complicated by Acute Pancreatitis. <i>Pancreas</i> , 2005, 30, 382-384.	0.5	46
93	Plasma transforming growth factor \hat{I}^21 , metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 in acute viral hepatitis type B. <i>Regulatory Peptides</i> , 2005, 131, 54-58.	1.9	6
94	Epidemiological characteristics of inflammatory bowel disease in North-Eastern Poland. <i>World Journal of Gastroenterology</i> , 2005, 11, 2630.	1.4	39
95	Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. <i>World Journal of Gastroenterology</i> , 2005, 11, 400.	1.4	30
96	Plasma interleukin-18 reflects severity of ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2005, 11, 605.	1.4	31
97	Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor- \hat{I}^21 , metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2005, 11, 6833.	1.4	8
98	Specific ssDNA concentration in liver tissue as an index of apoptosis in hepatitis C virus-infected patients. <i>World Journal of Gastroenterology</i> , 2005, 11, 6130.	1.4	1
99	Increased Plasma Transforming Growth Factor- \hat{I}^21 Is Associated with Disease Progression in HIV-1-Infected Patients. <i>Viral Immunology</i> , 2004, 17, 109-113.	0.6	63
100	Plasma interleukin-18 is associated with viral load and disease progression in HIV-1-infected patients. <i>Microbes and Infection</i> , 2004, 6, 1273-1277.	1.0	30
101	Effect of lamivudine treatment on plasma levels of transforming growth factor \hat{I}^21 , tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2004, 10, 2661.	1.4	11
102	Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 as biomarkers of ulcerative colitis activity. <i>World Journal of Gastroenterology</i> , 2003, 9, 2843.	1.4	42